GIGABYTE
17.5.2023 03:31:33 CEST | Business Wire | Press release
GIGABYTE, a leading innovator of computer hardware and server solutions, announces its unprecedented exhibits at COMPUTEX 2023. Resonating its theme “Future of COMPUTING”, GIGABYTE is unveiling its all-around technical achievements, including industry-leading AI/HPC servers, green computing solutions, gaming and creator products, industrial PC, AI smart securities, and autonomous vehicle technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005112/en/
GIGABYTE to Introduce Leading-Edge AI Solutions and Computers at COMPUTEX 2023, Unveiling “Future of COMPUTING” (Graphic: Business Wire)
Besides product exhibits, GIGABYTE will hold a four-day Tech Talk with speakers from AMD, Ampere, Intel, and NVIDIA, sharing insights about how the future of computing is reshaping the technology landscapes. The exhibition will be held from May 30th to June 2nd on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.
Take the Lead in the AI Era with GIGABYTE’s Trailblazing GPU/HPC Servers
The emergence of ChatGPT and various generative AI applications are making huge waves of industry evolution, driving all-time demand for AI computing servers. At COMPUTEX, GIGABYTE and its subsidiary, Giga Computing, are unveiling a cutting-edge lineup of GPU-accelerated servers and HPC servers. These solutions are aimed at accelerating exascale data analysis, deep learning, machine learning, inferencing, large language models (LLM), and generative AI training tasks, unlocking the unparalleled breakthroughs of AI development.
The latest lineup of GPU/HPC server solutions is powered by the latest CPU platform, GPU accelerator cards, and AI deep learning and inference technologies from leading tech partners. With GIGABYTE’s exclusive density-optimized server design and cooling technology, AI computing servers can achieve superior performance and energy efficiency, allowing enterprises and institutes to become the front-runner in AI competition.
Strike the Goals of Data Center Sustainability with GIGABYTE’s Immersion Cooling Solutions
The advent of AI technology has raised concerns about surging electricity consumption and carbon emissions, leading to the growing demand for data center cooling solutions designed to save power, boost computing performance, and reduce total cost of ownership (TCO). For the first time, GIGABYTE is showcasing three models of immersion cooling tanks and corresponding server series, demonstrating its widely acclaimed green computing solutions at COMPUTEX.
GIGABYTE's immersion cooling solutions have established admirable standards in energy efficiency and cost-effectiveness; therefore, they have been adopted by global semiconductor giants, telecommunication services, and European top research centers. GIGABYTE’s self-developed total solutions include the immersion cooling tanks, server configuration designs, and automatic monitoring and adjustment mechanisms, allowing enterprises and institutions to embrace sustainability and achieve innovation breakthroughs.
Explore the Gaming and Creator Computers with Lightspeed Overlocking
In addition to enterprise solutions, GIGABYTE is exhibiting a comprehensive computer portfolio, including the 2023 Red Dot Design Award-winning AORUS and AERO motherboards, graphics cards, and laptops, as well as STEALTH 500 computer assembly kit that won CES Innovation Award, SSD and large-size 4K monitors. All of these demonstrate GIGABYTE’s technical prowess and exceptional aesthetics. Tech enthusiasts at the booth will be thrilled to explore how GIGABYTE’s computers are pushing the performance beyond the limits and offering immersive experiences.
Grasp the Insights of Industry-Leading AI Trends at GIGABYTE Tech Talk
During the four-day COMPUTEX exhibition, GIGABYTE’s booth is holding Tech Talk sessions with diverse topics. Speakers from technology giants will share first-hand insights of AI advancements and green computing technologies, delivering various perspectives of “Future of COMPUTING” to the audiences.
Visit GIGABYTE’s COMPUTEX event page.
Subscribe to GIGABYTE newsletter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom